Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29583072 | 1.00 | MAPT (0.47) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL2017985 | 0.84 | MAPT (0.67) | MAPTMEN1KMT2ANISCH | |
| SCHEMBL29511657 | 0.84 | MAPT (0.67) | MAPTMEN1KMT2ANISCH | |
| SCHEMBL30222010 | 0.83 | MAPT (0.42) | MAPTCYP1A2TDP1L3MBTL1 | |
| SCHEMBL2023656 | 0.83 | MAPT (0.42) | MAPTCYP1A2TDP1L3MBTL1 | |
| SCHEMBL3274613 | 0.83 | MAPT (0.62) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL29350914 | 0.81 | MAPT (0.47) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL9224964 | 0.81 | MAPT (0.47) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL16241795 | 0.76 | MAPT (0.54) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL19222664 | 0.75 | MAPT (0.53) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593439-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2016-08-17 | — | — | EP | claimed |
| EP-2593439-A2 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-05-22 | — | — | EP | claimed |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | claimed |
| WO-2012009699-A2 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | WO | claimed |
| EP-3415504-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2018-12-19 | — | — | EP | disclosed |
| EP-3056486-B1 | PROCESS FOR PREPARING INTERMEDIATES FOR ANTIVIRAL COMPOUNDS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2887941-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-07-11 | — | — | EP | disclosed |
| US-9732045-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160332973-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. | 2016-11-17 | — | — | US | disclosed |
| US-9434698-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-3056486-A2 | PROCESS FOR PREPARING INTERMEDIATES FOR ANTIVIRAL COMPOUNDS | AbbVie Bahamas Ltd. (BS) | 2016-08-17 | — | — | EP | disclosed |
| EP-2593439-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2016-08-17 | — | — | EP | disclosed |
| US-9255074-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150191437-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8895737-B2 | Process for preparing antiviral compounds | ABBVIE INC. | 2014-11-25 | — | — | US | disclosed |
| US-20130224149-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224149-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | MAPT 4064/4885CYP1A2 673/4885CYP2C9 336/4885 |
| US-20160332973-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | MAPT 4064/4885CYP1A2 673/4885CYP2C9 336/4885 |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, MAVS, RNASE1 | MAPT 4108/4885CYP1A2 803/4885CYP2C9 351/4885 |
| US-20150191437-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | MAPT 4064/4885CYP1A2 673/4885CYP2C9 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.